Picardi M, Vincenzi A. Is it time to increase the liposomal doxorubicin dosage for frontline therapy in young adults and adults with classic Hodgkin lymphoma? Comment on: “Is it time to reduce the doxorubicin dosage in Hodgkin lymphoma therapy?”. haematol [Internet]. 2026Sep.1 [cited 2026Oct.16];111(9):3178-80. Available from: https://haematologica.org/article/view/14173